About Us - China Plant Extracts Manufacturers Suppliers Factory

Company Profile

Shaanxi Medibridge Biotech Co., Ltd. is a high-tech enterprise jointly established by a British research institution and a scientific research institute affiliated with Tsinghua University in China. Founded in 2011, the company's headquarters is located in the High-Tech Zone of Xi'an, Shaanxi Province, China. Medibridge Biotech integrates research and development, production, and sales, with extensive scientific research experience and a high-standard quality control system. The company focuses on the R&D of research-grade peptides, small-molecule drugs, pharmaceutical intermediates, natural plant and animal extracts, organic synthesis and customization, as well as CMO/CDMO contract manufacturing services. In recent years, the company has experienced rapid business growth, particularly in the fields of peptides, APIs, natural extracts, and pharmaceutical intermediates.

Our History

2011

2014

2016

2019

2021

2024

2025

2011

Shaanxi Medibridge Biotech was established and completed its initial production line and pilot production. Meanwhile, the peptide SPPS platform was built, and the first gram-scale custom synthesis was successfully delivered.

2014

The company obtained ISO22000/HACCP and Kosher/Halal certifications, and established a core raw material base and traceability system.

2016

The peptide kilogram-scale automated synthesis and preparative HPLC production lines were launched. The GMP system was formed and passed its first customer audit.

2019

Achieved breakthroughs in long-peptide and difficult-sequence synthesis technologies. The first Drug Master File (DMF/ASMF) was submitted, marking entry into a new supply chain.At the same time, exports to Europe and the United States accelerated, and the product portfolio was upgraded.

2021

Integrated ERP, MES, and LIMS systems with electronic batch records for the first time, and obtained BRC/FSSC 22000 and organic certifications.

2024

Established standardized high-purity production, customized formulation, and global rapid delivery capabilities.
By early 2024, total custom synthesis deliveries reached USD 9.8723 million, continuing on a growth trajectory.

2025

Phase II GMP workshop project approval obtained. High-value modified peptides and CDMO services have become the main growth drivers.

Our Factory

Shaanxi Medibridge Biotech Co., Ltd. is a "dual-engine" platform enterprise focusing on peptide synthesis R&D and natural plant and animal extract production. Its main R&D base is located in the Health Industry Park of Xianyang, Shaanxi Province, covering an area of 4,500 m² and operating in strict compliance with GMP management standards. In addition, branch facilities have been established in Hangzhou, Nanjing, and Wuhan. Relying on SPPS/LPPS hybrid peptide synthesis technologies and green extraction processes such as supercritical CO₂ and membrane separation, Medibridge Biotech provides integrated solutions ranging from milligram- to kilogram-scale peptide customization and process scale-up, to standardized and tailor-made large-scale production and compounding of natural extracts.

Our quality system and digitalization are fully integrated, equipped with advanced analytical instruments including HPLC, UPLC, LC-MS, GC, and ICP-MS. Analytical methods align with pharmacopeia and food-related standards, serving multiple sectors such as pharmaceuticals, nutrition and health, personal care, and scientific research - creating higher value for customers through consistent quality and a traceable supply chain.